AstraZeneca PLC
Explore AstraZeneca
Core profile pages, annual revenue records, and related research hubs for this company.
AstraZeneca PLC
Explore AstraZeneca
Core profile pages, annual revenue records, and related research hubs for this company.
Business Model Analysis
Annual Revenue: $58.7B
The company maintains a harmonised listing on the London Stock Exchange, Nasdaq Stockholm, and the New York Stock Exchange, and sells medicines in more than 125 countries. Collaboration Revenue, which includes milestone payments, upfront fees from partnership arrangements, and royalties on out-licensed intellectual property, added $1.1 billion in 2025. Surprisingly, the rare disease market's high barriers to entry, including complex biologics manufacturing, small patient populations, and specialized diagnostic requirements, protect AstraZeneca's pricing power but also limit the addressable market size. These targets require not merely product success but also commercial execution, pricing negotiation, and reimbursement approval across dozens of regulatory jurisdictions. Here's why: the merger also triggered regulatory scrutiny, with the U.S. Federal Trade Commission requiring the divestiture of Zeneca's rights to levobupivacaine, a long-acting local anesthetic, to preserve competition in a market where Astra was the dominant supplier.
AstraZeneca's growth strategy centers on oncology expansion, rare disease from Alexion, cardiovascular and renal medicines, respiratory and immunology launches, pipeline execution, and manufacturing/R&D investment.
AstraZeneca earns from patented prescription medicines across oncology and other specialty therapy areas.
Oncology uptake, new indications, and pipeline approvals drive AstraZeneca growth.
Oncology franchise growth, China exposure, and late-stage pipeline are key variables.
R&D and manufacturing intensive typical of large biopharma.
Pipeline productivity determines whether new medicines can replace patent expirations and sustain long-term revenue growth.